Australia's most trusted
source of pharma news
Monday, 13 July 2026
Posted 13 July 2026 PM
Aegros has completed building Australia’s second large scale plasma fractionation facility, joining CSL’s long-established footprint.
The 400m2 plant, located in Macquarie Park, Sydney, utilises the Australian biotech’s manufacturing technology Haemafrac, which delivers higher protein production efficiency while reducing manufacturing costs.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.